The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis
Keiko Imamura(Kyoto University), Yuishin Izumi(Tokushima University), Akira Watanabe(Kyoto University), Kayoko Tsukita(Kyoto University), Knut Woltjen(Kyoto University), Takuya Yamamoto(Kyoto University), Akitsu Hotta(Kyoto University), Takayuki Kondo(Kyoto University), Shiho Kitaoka(Kyoto University), Akira Ohta(Kyoto University), Akito Tanaka(Kyoto University), Dai Watanabe(Kyoto University), Mitsuya Morita(Jichi Medical University), Hiroshi Takuma(University of Tsukuba), Akira Tamaoka(University of Tsukuba), Tilo Kunath(MRC Centre for Regenerative Medicine), Selina Wray(National Hospital for Neurology and Neurosurgery), Hirokazu Furuya(Kōchi University), Takumi Era(Kumamoto University), Kouki Makioka(Gunma University), Koichi Okamoto, Takao Fujisawa(The University of Tokyo), Hideki Nishitoh(University of Miyazaki), Kengo Homma(The University of Tokyo), Hidenori Ichijo(The University of Tokyo), Jean‐Pierre Julien(Institut Universitaire en Santé Mentale de Québec), Nanako Obata(Tokyo Metropolitan Institute of Medical Science), Masato Hosokawa(Tokyo Metropolitan Institute of Medical Science), Haruhiko Akiyama(Tokyo Metropolitan Institute of Medical Science), Satoshi Kaneko(Kansai Medical University), Takashi Ayaki(Kyoto University), Hidefumi Ito(Wakayama Medical University), Ryuji Kaji(Kyoto University), Ryōsuke Takahashi(Kyoto University), Shinya Yamanaka(Gladstone Institutes), Haruhisa Inoue(Kyoto University)
Cited by 254Open Access
Abstract
mutation, suggesting that Src/c-Abl may be a potentially useful target for developing new drugs to treat ALS.
Related Papers
No related papers found
Powered by citation graph analysis